The rumors are true: Teva does indeed have eyes for Mylan. And after months of speculation, its bid is here.
Fueled by strong sales for its latest cardio drug and a promising pipeline, Switzerland's Actelion says it's on the lookout for acquisitions but remains wary of paying the big premiums that have become commonplace in pharma.
Satisfying EU regulators on Zimmer's Biomet deal, Italian orthopedics company to buy trio of divested products
Lima Corporate, an established Italian orthopedics company, is buying the three product lines from Zimmer and Biomet that the European Commission had last month required them to sell to complete their acquisition deal. The deal complements its own newly launched total knee system.
Daiichi Sankyo has had enough of trying to make money in the Indian generic drug industry. The Japanese drugmaker, which faces patent cliff issues, is selling off its stake in Sun Pharmaceutical just weeks after it closed on the all-stock deal selling Ranbaxy Laboratories to Sun for $3.2 billion.
St. Jude Medical will buy portfolio company Spinal Modulation. The startup has submitted a PMA for its Axium Neurostimulator System to treat chronic pain. St. Jude will pay up to $175 million upfront with additional undisclosed payments upon FDA approval of the Axium system and with the achievement of undisclosed revenue targets.
Patterson Companies is said to be looking to shed its rehabilitation supply business in a deal that could reap the Minnesota-based medical device supplier up to $600 million, Reuters reported.
Those Mylan-Teva tie-up rumors just won't go away, and now, reports say the Israeli drugmaker is weighing a play for its generics rival. But make no mistake, Mylan said Friday: It wants to keep flying solo, and that includes wrapping up some M&A of its own.
Fitch Ratings is raising the flag on pharma M&A. The credit ratings agency says the current spate of dealmaking is putting some pressure on European Big Pharma players.
Zimmer announced that the "outside date" for completing its merger with Biomet has been postponed from April 24, 2015, to July 23, 2015.
Actavis is trying to encourage an appeals court to let it force patients over to a new, patent-protected version of Alzheimer's treatment Namenda. Hundreds of millions in sales rest on the decision. But so far, the judges aren't offering any clues about their answer.